Description
GD1 is currently under investigation for its potential use in colorectal cancer (CRC) and has not yet been approved by the FDA. Its clinical efficacy and safety profile are still being evaluated in ongoing clinical trials, primarily as a single-agent therapy or in combination with other targeted agents.
Mechanism of Action
GD1 is an investigational agent with mechanisms of action currently under research, primarily focusing on inhibiting specific pathways involved in colorectal cancer progression.
Side Effects
Nausea; Vomiting; Diarrhea; Fatigue; Hematological toxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04842812
med_phase_prefix1
Recruiting
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
China